Compare LCNB & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | HELP |
|---|---|---|
| Founded | 1877 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.7M | 249.0M |
| IPO Year | 1999 | N/A |
| Metric | LCNB | HELP |
|---|---|---|
| Price | $16.95 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 29.1K | ★ 708.9K |
| Earning Date | 04-23-2026 | 07-01-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $10.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $4.29 |
| 52 Week High | $17.89 | $8.55 |
| Indicator | LCNB | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 62.62 | 47.91 |
| Support Level | $17.08 | $4.40 |
| Resistance Level | $17.79 | $8.55 |
| Average True Range (ATR) | 0.41 | 0.29 |
| MACD | 0.21 | 0.14 |
| Stochastic Oscillator | 89.43 | 78.45 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.